1
|
Molina JR, Gozgit JM, Vasbinder MM, Abo RP, kunii K, Kuplast-Barr KG, Gui B, Nayak SP, Minissale E, Swinger KK, Wigle TJ, Lu AZ, Blackwell DJ, Majer CR, Ren Y, Bamberg E, Niepel M, Mo JR, Church WD, Mady AS, Song J, Varsamis ZA, Utley L, Rao PE, Mitchison TJ, Kuntz KW, Richon VM, McEachern K, Keilhack H. Abstract 2154: PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-2154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Targeting cytosolic nucleic acid sensing pathways to activate the Type I interferon (IFN) response is an emerging therapeutic strategy being explored in oncology. The PARP family consists of seventeen enzymes that regulate fundamental biological processes including response to cellular stress. PARP7 (TIPARP) is a stress-induced mono-ART that catalyzes the transfer of a single unit of ADP-ribose onto substrates (MARylation) to regulate their function and plays a role in suppressing the Type I IFN response in tumor cells (Gozgit 2021 Cancer Cell). RBN-2397 is the first potent and selective small molecule inhibitor of PARP7 catalytic function. To investigate the cell autonomous effects of PARP7 inhibition, we performed a cell line screen to identify PARP7 dependent cancer cell lines. We found that treatment of a subset of lines across several cancers led to a robust decrease in cell viability. Additionally, dosing of tumor bearing mice led to complete regressions in NCI-H1373 lung cancer xenografts. To investigate the mechanism of action (MOA) leading to decreased cell viability, we treated NCI-H1373 cells with RBN-2397 and found accumulation of cells in the G0/G1 phase of the cell cycle indicative of a cell cycle arrest. This arrest in NCI-H1373 cells was associated with the induction of senescence and increased mRNA expression of senescence associated secretory phenotype (SASP) genes. To evaluate the in vivo MOA, we performed an NCI-H1373 xenograft study and collected tumors after 7 days of RBN-2397 treatment. PARP7 inhibition led to decreased expression of Ki67, and increased expression of P21 and cleaved caspase-3, suggesting decreased proliferation and increased apoptosis. Increased expression of SASP genes was also observed in RBN-2397 treated tumors. Finally, we investigated transcriptional changes after RBN-2397 treatment by RNA sequencing. In addition to the effects observed in Type I IFN signaling, we also observed differential expression of genes associated with other pathways including autophagy and energy metabolism. Further evaluation of key autophagy proteins revealed that RBN-2397 affects autophagy flux and leads to a decrease in the oxygen consumption rate of cells and reduced ATP production from the mitochondria, suggesting that a change in energy metabolism may be related to the tumor intrinsic effect of RBN-2397. In summary, we show treatment of cancer cells with RBN-2397 not only leads to activation of tumor cell IFN signaling, but also causes G1 arrest and senescence, and changes in cancer cell autophagy and energy metabolism. In vivo, RBN-2397 treatment leads to complete tumor regressions in xenografts accompanied by decreased proliferation and increased apoptosis of tumor cells. RBN-2397 is currently being evaluated in the clinic as single agent in selected cancer types (NCT04053673) and in combination with anti-PD-1 therapies.
Citation Format: Jennifer R. Molina, Joseph M. Gozgit, Melissa M. Vasbinder, Ryan P. Abo, Kaiko kunii, Kristy G. Kuplast-Barr, Bin Gui, Sunaina P. Nayak, Elena Minissale, Kerren K. Swinger, Tim J. Wigle, Alvin Z. Lu, Danielle J. Blackwell, Christina R. Majer, Yue Ren, Ellen Bamberg, Mario Niepel, Jan-Rung Mo, William D. Church, Ahmed S. Mady, Jeff Song, Zacharenia A. Varsamis, Luke Utley, Patricia E. Rao, Timoty J. Mitchison, Kevin W. Kuntz, Victoria M. Richon, Kristen McEachern, Heike Keilhack. PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2154.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Bin Gui
- 1Ribon Therapeutics, Cambridge, MA
| | | | | | | | | | | | | | | | - Yue Ren
- 1Ribon Therapeutics, Cambridge, MA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Gozgit JM, Vasbinder MM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B, Lu AZ, Molina JR, Minissale E, Swinger KK, Wigle TJ, Blackwell DJ, Majer CR, Ren Y, Niepel M, Varsamis ZA, Nayak SP, Bamberg E, Mo JR, Church WD, Mady ASA, Song J, Utley L, Rao PE, Mitchison TJ, Kuntz KW, Richon VM, Keilhack H. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell 2021; 39:1214-1226.e10. [PMID: 34375612 DOI: 10.1016/j.ccell.2021.06.018] [Citation(s) in RCA: 65] [Impact Index Per Article: 21.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 05/25/2021] [Accepted: 06/25/2021] [Indexed: 01/07/2023]
Abstract
PARP7 is a monoPARP that catalyzes the transfer of single units of ADP-ribose onto substrates to change their function. Here, we identify PARP7 as a negative regulator of nucleic acid sensing in tumor cells. Inhibition of PARP7 restores type I interferon (IFN) signaling responses to nucleic acids in tumor models. Restored signaling can directly inhibit cell proliferation and activate the immune system, both of which contribute to tumor regression. Oral dosing of the PARP7 small-molecule inhibitor, RBN-2397, results in complete tumor regression in a lung cancer xenograft and induces tumor-specific adaptive immune memory in an immunocompetent mouse cancer model, dependent on inducing type I IFN signaling in tumor cells. PARP7 is a therapeutic target whose inhibition induces both cancer cell-autonomous and immune stimulatory effects via enhanced IFN signaling. These data support the targeting of a monoPARP in cancer and introduce a potent and selective PARP7 inhibitor to enter clinical development.
Collapse
Affiliation(s)
- Joseph M Gozgit
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
| | - Melissa M Vasbinder
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Ryan P Abo
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Kaiko Kunii
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | | | - Bin Gui
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Alvin Z Lu
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Jennifer R Molina
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Elena Minissale
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Kerren K Swinger
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Tim J Wigle
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | | | - Christina R Majer
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Yue Ren
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Mario Niepel
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | | | - Sunaina P Nayak
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Ellen Bamberg
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Jan-Rung Mo
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - W David Church
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Ahmed S A Mady
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Jeff Song
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Luke Utley
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | | | - Timothy J Mitchison
- Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Warren Alpert 536, Boston, MA 02115, USA
| | - Kevin W Kuntz
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Victoria M Richon
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Heike Keilhack
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
| |
Collapse
|
3
|
Wigle TJ, Blackwell DJ, Schenkel LB, Ren Y, Church WD, Desai HJ, Swinger KK, Santospago AG, Majer CR, Lu AZ, Niepel M, Perl NR, Vasbinder MM, Keilhack H, Kuntz KW. In Vitro and Cellular Probes to Study PARP Enzyme Target Engagement. Cell Chem Biol 2021; 27:877-887.e14. [PMID: 32679093 DOI: 10.1016/j.chembiol.2020.06.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Revised: 05/18/2020] [Accepted: 06/15/2020] [Indexed: 02/06/2023]
Abstract
Poly(ADP-ribose) polymerase (PARP) enzymes use nicotinamide adenine dinucleotide (NAD+) to modify up to seven different amino acids with a single mono(ADP-ribose) unit (MARylation deposited by PARP monoenzymes) or branched poly(ADP-ribose) polymers (PARylation deposited by PARP polyenzymes). To enable the development of tool compounds for PARP monoenzymes and polyenzymes, we have developed active site probes for use in in vitro and cellular biophysical assays to characterize active site-directed inhibitors that compete for NAD+ binding. These assays are agnostic of the protein substrate for each PARP, overcoming a general lack of knowledge around the substrates for these enzymes. The in vitro assays use less enzyme than previously described activity assays, enabling discrimination of inhibitor potencies in the single-digit nanomolar range, and the cell-based assays can differentiate compounds with sub-nanomolar potencies and measure inhibitor residence time in live cells.
Collapse
Affiliation(s)
- Tim J Wigle
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
| | | | - Laurie B Schenkel
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Yue Ren
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - W David Church
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Hetvi J Desai
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Kerren K Swinger
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Andrew G Santospago
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Christina R Majer
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Alvin Z Lu
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Mario Niepel
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Nicholas R Perl
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Melissa M Vasbinder
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Heike Keilhack
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| | - Kevin W Kuntz
- Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA
| |
Collapse
|
4
|
Shambharkar P, Blackwell DJ, Vasbinder MM, Schenkel LB, Kunii K, Lemera JL, Kuplast-Barr KG, Ren Y, Bamberg E, Church WD, Majer CR, Utley L, McEachern K, Niepel M, Wigle TJ, Kuntz KW, Richon VM, Keilhack H, Gozgit JM. Abstract 1344: Small molecule inhibitor of CD38 modulates its intra- and extracellular functions leading to antitumor activity. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1344] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CD38 is an ADP-ribosyl cyclase that converts NAD+ to ADP-ribose (ADPR) or cyclic ADPR (cADPR) and nicotinamide. The enzyme can exist in either an ecto- or endo-catalytic orientation with different sub-cellular localization, and therefore can regulate internal and external NAD+ pools. Both NAD+ and cADPR can impact T cell fitness and effector function, and CD38 has been shown to be increased in settings of chronic T cell activation. CD38 can mediate the non-canonical generation of the immune suppressive adenosine by catabolizing extracellular NAD+ resulting in immunosuppression in the microenvironment. Upon immune checkpoint inhibitor (ICI) therapy, CD38 is upregulated on cancer cells to drive ICI resistance. Therefore CD38, through its catalytic activity, has been implicated in tumor immune suppression and ICI resistance. Genetic knockout of CD38 has been shown to prevent tumor growth and improve T cell fitness. Here, we describe the effects of CD38 inhibition using a small molecule inhibitor on these key metabolites in various cellular and tumor models.
RBN013209 is a potent and selective small molecule inhibitor of CD38 catalytic function. We demonstrate that inhibition of CD38 with RBN013209 prevents conversion of extracellular NAD+ to ADPR or cADPR in cancer cell lines and PBMCs. Similarly, RBN013209 inhibited intracellular CD38 activity and elevated intracellular NAD+ levels in cultured human primary T cells. Oral administration of RBN013209 to naïve mice resulted in dose-dependent elevation of NAD+ and reduction of ADPR in various tissues such as spleen and liver. We next assessed the expression of CD38 protein by immunohistochemistry following ICI treatment in various syngeneic cancer models to select a model for efficacy studies. We observed increases in CD38 expression on tumor cells and infiltrating immune cells in MC38 colon cancer and B16-F10 and Cloudman S91 melanoma models. In the MC38 tumor model, we observed single agent antitumor activity with RBN013209 that was associated with changes in NAD+ and ADPR. In B16-F10 tumor-bearing mice, we observed antitumor activity with RBN013209 in combination with anti-PD-L1 therapy. To evaluate CD38 as a biomarker in clinical samples, we assessed and confirmed the tumor expression of CD38 protein from lung, prostate and kidney cancer patients.
Here, we show that inhibition of CD38 with a small molecule affects both intra- and extra-cellular CD38 activity and modulates key metabolites playing an important role in immunomodulation. Further, our data indicate that CD38 is increased by ICI treatment and that inhibition of CD38 can lead to antitumor activity.
Citation Format: Prashant Shambharkar, Danielle J. Blackwell, Melissa M. Vasbinder, Laurie B. Schenkel, Kaiko Kunii, Jenkins L. Lemera, Kristy G. Kuplast-Barr, Yue Ren, Ellen Bamberg, W. David Church, Christina R. Majer, Luke Utley, Kristen McEachern, Mario Niepel, Tim J. Wigle, Kevin W. Kuntz, Victoria M. Richon, Heike Keilhack, Joseph M. Gozgit. Small molecule inhibitor of CD38 modulates its intra- and extracellular functions leading to antitumor activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1344.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Yue Ren
- Ribon Therapeutics, Cambridge, MA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Wigle TJ, Ren Y, Molina JR, Blackwell DJ, Schenkel LB, Swinger KK, Kuplast-Barr K, Majer CR, Church WD, Lu AZ, Mo J, Abo R, Cheung A, Dorsey BW, Niepel M, Perl NR, Vasbinder MM, Keilhack H, Kuntz KW. Targeted Degradation of PARP14 Using a Heterobifunctional Small Molecule. Chembiochem 2021; 22:2107-2110. [PMID: 33838082 DOI: 10.1002/cbic.202100047] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 04/07/2021] [Indexed: 01/07/2023]
Abstract
PARP14 is an interferon-stimulated gene that is overexpressed in multiple tumor types, influencing pro-tumor macrophage polarization as well as suppressing the antitumor inflammation response by modulating IFN-γ and IL-4 signaling. PARP14 is a 203 kDa protein that possesses a catalytic domain responsible for the transfer of mono-ADP-ribose to its substrates. PARP14 also contains three macrodomains and a WWE domain which are binding modules for mono-ADP-ribose and poly-ADP-ribose, respectively, in addition to two RNA recognition motifs. Catalytic inhibitors of PARP14 have been shown to reverse IL-4 driven pro-tumor gene expression in macrophages, however it is not clear what roles the non-enzymatic biomolecular recognition motifs play in PARP14-driven immunology and inflammation. To further understand this, we have discovered a heterobifunctional small molecule designed based on a catalytic inhibitor of PARP14 that binds in the enzyme's NAD+ -binding site and recruits cereblon to ubiquitinate it and selectively target it for degradation.
Collapse
Affiliation(s)
- Tim J Wigle
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Yue Ren
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Jennifer R Molina
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | | | - Laurie B Schenkel
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Kerren K Swinger
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Kristy Kuplast-Barr
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Christina R Majer
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - W David Church
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Alvin Z Lu
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Jason Mo
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Ryan Abo
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Anne Cheung
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Bryan W Dorsey
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Mario Niepel
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Nicholas R Perl
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Melissa M Vasbinder
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Heike Keilhack
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| | - Kevin W Kuntz
- Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140, USA
| |
Collapse
|
6
|
Schenkel LB, Molina JR, Swinger KK, Abo R, Blackwell DJ, Lu AZ, Cheung AE, Church WD, Kunii K, Kuplast-Barr KG, Majer CR, Minissale E, Mo JR, Niepel M, Reik C, Ren Y, Vasbinder MM, Wigle TJ, Richon VM, Keilhack H, Kuntz KW. A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants. Cell Chem Biol 2021; 28:1158-1168.e13. [PMID: 33705687 DOI: 10.1016/j.chembiol.2021.02.010] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Revised: 12/18/2020] [Accepted: 02/11/2021] [Indexed: 11/28/2022]
Abstract
PARP14 has been implicated by genetic knockout studies to promote protumor macrophage polarization and suppress the antitumor inflammatory response due to its role in modulating interleukin-4 (IL-4) and interferon-γ signaling pathways. Here, we describe structure-based design efforts leading to the discovery of a potent and highly selective PARP14 chemical probe. RBN012759 inhibits PARP14 with a biochemical half-maximal inhibitory concentration of 0.003 μM, exhibits >300-fold selectivity over all PARP family members, and its profile enables further study of PARP14 biology and disease association both in vitro and in vivo. Inhibition of PARP14 with RBN012759 reverses IL-4-driven protumor gene expression in macrophages and induces an inflammatory mRNA signature similar to that induced by immune checkpoint inhibitor therapy in primary human tumor explants. These data support an immune suppressive role of PARP14 in tumors and suggest potential utility of PARP14 inhibitors in the treatment of cancer.
Collapse
Affiliation(s)
- Laurie B Schenkel
- Department of Molecular Discovery, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA; MOMA Therapeutics, Cambridge, MA 02142, USA
| | - Jennifer R Molina
- Department of Biological Sciences, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Kerren K Swinger
- Department of Molecular Discovery, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA; Xilio Therapeutics, Waltham, MA 02451, USA
| | - Ryan Abo
- Department of Biological Sciences, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA; Obsidian Therapeutics, Cambridge, MA 02138, USA
| | - Danielle J Blackwell
- Department of Molecular Discovery, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Alvin Z Lu
- Department of Biological Sciences, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Anne E Cheung
- Department of Biological Sciences, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA; A2Empowerment, Arlington, MA 02474, USA
| | - W David Church
- Department of Molecular Discovery, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Kaiko Kunii
- Department of Biological Sciences, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Kristy G Kuplast-Barr
- Department of Biological Sciences, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Christina R Majer
- Department of Molecular Discovery, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Elena Minissale
- Department of Biological Sciences, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Jan-Rung Mo
- Department of Biological Sciences, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Mario Niepel
- Department of Biological Sciences, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Christopher Reik
- Department of Molecular Discovery, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA; Bain & Company, Boston, MA 02116, USA
| | - Yue Ren
- Department of Molecular Discovery, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Melissa M Vasbinder
- Department of Molecular Discovery, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Tim J Wigle
- Department of Molecular Discovery, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Victoria M Richon
- Department of Molecular Discovery, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA; Department of Biological Sciences, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Heike Keilhack
- Department of Biological Sciences, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA
| | - Kevin W Kuntz
- Department of Molecular Discovery, Ribon Therapeutics, Inc., Cambridge, MA 02140, USA.
| |
Collapse
|
7
|
Gozgit JM, Vasbinder MM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B, Lu AZ, Swinger KK, Wigle TJ, Blackwell DJ, Majer CR, Ren Y, Niepel M, Varsamis ZA, Nayak SP, Bamberg E, Mo JR, Church W, Song J, Utley L, Rao PE, Mitchison TJ, Kuntz KW, Richon VM, Keilhack H. Abstract 3405: PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition leads to tumor regression. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-3405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Targeting cytosolic nucleic acid sensing pathways and the Type I interferon (IFN) response is an emerging therapeutic strategy being explored in oncology. PARP7 is a member of the monoPARP class of enzymes, which catalyze the transfer of single units of ADP-ribose onto substrates to change their function. PARP7 expression is increased by cellular stress and aromatic hydrocarbons, and the PARP7 gene is amplified in cancers, especially in those of the upper aerodigestive tract. PARP7 has also been reported to negatively regulate the Type I IFN response by interacting with TBK1 during viral infection. Herein, we identify PARP7 as a novel negative regulator of cytosolic nucleic acid sensing in tumor cells.
RBN-2397, is a potent and selective small molecule inhibitor of PARP7 catalytic function. We identified a subset of cancers exhibiting dependency on PARP7 for proliferation and found that cell lines with higher baseline expression of interferon stimulated genes were more sensitive. We further show that inhibition of PARP7 by RBN-2397 restores Type I IFN signaling as demonstrated by the induction of STAT1 phosphorylation and up-regulation of genes enriched for Type I IFN signaling in NCI-H1373 lung cancer cells. We examined the antitumor effects of once daily orally administered RBN-2397 in SCID mice with subcutaneous NCIH1373 xenograft tumors and observed a dose-dependent effect of RBN-2397 on tumor growth, with regressions at dose levels ≥30 mg/kg. To evaluate the antitumor immune response in vivo, we administered RBN-2397 to CT26 tumor-bearing, immunocompetent BALB/c mice, and observed significant tumor growth inhibition at all dose levels with complete and durable regressions in a subset of mice. All of these tumor-free mice rejected a challenge of injected CT26 cells, but were able to develop 4T1 tumors, demonstrating induction of tumor-specific adaptive immune memory. The antitumor effects of RBN-2397 were further enhanced when combined with an immune checkpoint inhibitor, anti-PD1. Using CRISPR-Cas9 to knockout either TBK1 or IFNAR1 in CT26 cells, we demonstrated that RBN-2397 antitumor immunity is dependent on the effects of tumor-derived Type I interferon on immune cells.
Here, we show for the first time that cancer cells use PARP7 to suppress the Type I IFN response to cytosolic nucleic acids. We have discovered and developed RBN-2397, a first-in-class, potent and selective inhibitor of PARP7. We show RBN-2397 restores Type I IFN signaling in the tumor, causes complete tumor regressions and adaptive immunity in murine models. RBN-2397 is the first agent to enter clinical trials that targets this tumor-intrinsic vulnerability.
Citation Format: Joseph M. Gozgit, Melissa M. Vasbinder, Ryan P. Abo, Kaiko Kunii, Kristy G. Kuplast-Barr, Bin Gui, Alvin Z. Lu, Kerren K. Swinger, Tim J. Wigle, Danielle J. Blackwell, Christina R. Majer, Yue Ren, Mario Niepel, Zacharenia A. Varsamis, Sunaina P. Nayak, Ellen Bamberg, Jan-Rung Mo, William Church, Jeff Song, Luke Utley, Patricia E. Rao, Timothy J. Mitchison, Kevin W. Kuntz, Victoria M. Richon, Heike Keilhack. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition leads to tumor regression [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3405.
Collapse
Affiliation(s)
| | | | | | | | | | - Bin Gui
- 1Ribon Therapeutics, Inc, Cambridge, MA
| | | | | | | | | | | | - Yue Ren
- 1Ribon Therapeutics, Inc, Cambridge, MA
| | | | | | | | | | | | | | - Jeff Song
- 1Ribon Therapeutics, Inc, Cambridge, MA
| | | | | | | | | | | | | |
Collapse
|
8
|
Vasbinder MM, Gozgit JM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B, Lu AZ, Swinger KK, Wigle TJ, Blackwell DJ, Majer CR, Ren Y, Niepel M, Varsamis ZA, Nayak SP, Bamberg E, Mo JR, Church WD, Song J, Utley L, Rao PE, Mitchison TJ, Kuntz KW, Richon VM, Keilhack H. Abstract DDT02-01: RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-ddt02-01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways PARP7 is a monoPARP that catalyzes the transfer of single units of ADP-ribose onto substrates to change their function (MARylation). PARP7 expression is increased by cellular stresses, including aromatic hydrocarbons and the PARP7 gene is amplified in cancers, especially in those of the upper aerodigestive tract. PARP7 has also been reported to negatively regulate the Type I interferon (IFN) response by interacting with TBK1 during viral infection. As part of our drug discovery efforts to identify inhibitors of PARP7, we utilized structure-based drug design to optimize an unselective monoPARP inhibitor identified by screening Ribon's internal compound collection of PARP inhibitors. Further optimization of potency and physicochemical properties led to the discovery of RBN-2397, a potent and selective small molecule inhibitor of PARP7 catalytic function. A co-crystal structure of RBN-2397 demonstrated binding of the compound in the NAD+-binding pocket. Binding to cellular PARP7 is demonstrated by the ability of RBN-2397 to displace an active site probe in a NanoBRET assay. Functionally, RBN-2397 leads to the inhibition of MARylation of multiple intracellular proteins in PARP7-overexpressing SK-MES-1 cells. We identified a subset of cancers exhibiting dependency on PARP7 for proliferation. Cell lines with higher baseline expression of interferon stimulated genes are more sensitive to RBN-2397 in proliferation assays. We further show that inhibition of PARP7 by RBN-2397 restores Type I IFN signaling as demonstrated by the induction of STAT1 phosphorylation and upregulation of genes enriched for Type I IFN signaling in NCI-H1373 lung cancer cells. Oral dosing of RBN-2397 results in durable, complete tumor regression in a NCI-H1373 lung cancer xenograft and induces tumor-specific adaptive immune memory in an immunocompetent mouse cancer model that is dependent on tumor-derived Type I IFN signaling. Herein, we describe the discovery of the small molecule PARP7 inhibitor RBN-2397, the first therapeutic agent targeting PARP7 to enter clinical trials, and the first disclosure of the inhibitor. We demonstrate PARP7 is a novel therapeutic target and inhibition of PARP7 by RBN-2397 induces both cancer cell autonomous and immune stimulatory effects via enhanced IFN signaling.
Citation Format: Melissa M. Vasbinder, Joseph M. Gozgit, Ryan P. Abo, Kaiko Kunii, Kristy G. Kuplast-Barr, Bin Gui, Alvin Z. Lu, Kerren K. Swinger, Tim J. Wigle, Danielle J. Blackwell, Christina R. Majer, Yue Ren, Mario Niepel, Zacharenia A. Varsamis, Sunaina P. Nayak, Ellen Bamberg, Jan-Rung Mo, W David Church, Jeff Song, Luke Utley, Patricia E. Rao, Timothy J. Mitchison, Kevin W. Kuntz, Victoria M. Richon, Heike Keilhack. RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr DDT02-01.
Collapse
Affiliation(s)
- Melissa M. Vasbinder
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Joseph M. Gozgit
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Ryan P. Abo
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Kaiko Kunii
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Kristy G. Kuplast-Barr
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Bin Gui
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Alvin Z. Lu
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Kerren K. Swinger
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Tim J. Wigle
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Danielle J. Blackwell
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Christina R. Majer
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Yue Ren
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Mario Niepel
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Zacharenia A. Varsamis
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Sunaina P. Nayak
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Ellen Bamberg
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Jan-Rung Mo
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - W David Church
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Jeff Song
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Luke Utley
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Patricia E. Rao
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Timothy J. Mitchison
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Kevin W. Kuntz
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Victoria M. Richon
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| | - Heike Keilhack
- Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA
| |
Collapse
|
9
|
Wigle TJ, Blackwell DJ, Schenkel LB, Ren Y, Church WD, Desai HJ, Swinger KK, Santospago AG, Majer CR, Lu AZ, Niepel M, Perl NR, Vasbinder MM, Keilhack H, Kuntz KW. Abstract 506: A bespoke screening platform to study mono(ADP-ribosylation). Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Mono(ADP-ribosylation) (MARylation) and poly(ADP-ribosylation) (PARylation) are post-translational modifications deposited on multiple amino acids by PARP enzymes using nicotinamide adenine dinucleotide (NAD+) as the ADP-ribose donating substrate. While there are approved drugs and clinical trials on-going for inhibitors of the polyPARP enzymes that deposit poly(ADP-ribose) (specifically PARP1 and PARP2 inhibitors), monoPARP enzymes that deposit mono(ADP-ribose) are only recently gaining recognition for their role in cellular stress signaling, inflammation and cancer. However, there is a lack of chemical probes to study their function in cells and in vivo. An important first step to generating chemical probes for monoPARPs is to develop screening assays to enable determination of potency and selectivity of inhibitors during the hit finding and lead optimization phases. The development of enzyme assays is complicated by the fact that the substrates for the majority of the monoPARPs are unknown, and even for those with identified substrates, it is uncertain how they engage their substrates. Here we describe the development of robust high-throughput biochemical and cellular monoPARP assays that overcome the lack of knowledge around the substrates and construction of a family-wide screening panel. We highlight derivatized microplates that activate the enzymes to self-MARylate in dissociation enhanced lanthanide fluorescence assays (DELFIA), antibodies that recognize MARylation in in-cell western (ICW) and immunofluorescence (IF) assays, and NAD+-competitive molecular probes that are used to develop in vitro time-resolved fluorescence resonance energy transfer (TR-FRET) and cellular NanoLuc bioluminescence resonance energy transfer (NanoBRET) probe displacement assays. Additionally, we employ several methods to characterize inhibitor binding kinetics. These assays have been used in high-throughput screening campaigns of up to 500,000 compounds, as well as in the development of potent and selective inhibitors of multiple monoPARP enzymes including RBN012759, a tool compound for PARP14 that inhibits in vitro with an IC50 of 3 nM and in cells using with an IC50 of 9 nM, and is 300-fold selective over all other PARP enzymes.
Citation Format: Tim J. Wigle, Danielle J. Blackwell, Laurie B. Schenkel, Yue Ren, William D. Church, Hetvi J. Desai, Kerren K. Swinger, Andrew G. Santospago, Christina R. Majer, Alvin Z. Lu, Mario Niepel, Nicholas R. Perl, Melissa M. Vasbinder, Heike Keilhack, Kevin W. Kuntz. A bespoke screening platform to study mono(ADP-ribosylation) [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 506.
Collapse
Affiliation(s)
| | | | | | - Yue Ren
- Ribon Therapeutics, Inc, Cambridge, MA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Wigle TJ, Church WD, Majer CR, Swinger KK, Aybar D, Schenkel LB, Vasbinder MM, Brendes A, Beck C, Prahm M, Wegener D, Chang P, Kuntz KW. Forced Self-Modification Assays as a Strategy to Screen MonoPARP Enzymes. SLAS Discov 2019; 25:241-252. [PMID: 31855104 PMCID: PMC7036481 DOI: 10.1177/2472555219883623] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Mono(ADP-ribosylation) (MARylation) and poly(ADP-ribosylation) (PARylation) are
posttranslational modifications found on multiple amino acids. There are 12
enzymatically active mono(ADP-ribose) polymerase (monoPARP) enzymes and 4
enzymatically active poly(ADP-ribose) polymerase (polyPARP) enzymes that use
nicotinamide adenine dinucleotide (NAD+) as the ADP-ribose donating
substrate to generate these modifications. While there are approved drugs and
clinical trials ongoing for the enzymes that perform PARylation, MARylation is
gaining recognition for its role in immune function, inflammation, and cancer.
However, there is a lack of chemical probes to study the function of monoPARPs
in cells and in vivo. An important first step to generating chemical probes for
monoPARPs is to develop biochemical assays to enable hit finding, and
determination of the potency and selectivity of inhibitors. Complicating the
development of enzymatic assays is that it is poorly understood how monoPARPs
engage their substrates. To overcome this, we have developed a family-wide
approach to developing robust high-throughput monoPARP assays where the enzymes
are immobilized and forced to self-modify using biotinylated-NAD+,
which is detected using a dissociation-enhanced lanthanide fluorescence
immunoassay (DELFIA) readout. Herein we describe the development of assays for
12 monoPARPs and 3 polyPARPs and apply them to understand the potency and
selectivity of a focused library of inhibitors across this family.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Paul Chang
- Ribon Therapeutics Inc., Cambridge, MA, USA
| | | |
Collapse
|
11
|
Morrison MJ, Boriack-Sjodin PA, Swinger KK, Wigle TJ, Sadalge D, Kuntz KW, Scott MP, Janzen WP, Chesworth R, Duncan KW, Harvey DM, Lampe JW, Mitchell LH, Copeland RA. Identification of a peptide inhibitor for the histone methyltransferase WHSC1. PLoS One 2018; 13:e0197082. [PMID: 29742153 PMCID: PMC5942779 DOI: 10.1371/journal.pone.0197082] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Accepted: 04/25/2018] [Indexed: 02/06/2023] Open
Abstract
WHSC1 is a histone methyltransferase that is responsible for mono- and dimethylation of lysine 36 on histone H3 and has been implicated as a driver in a variety of hematological and solid tumors. Currently, there is a complete lack of validated chemical matter for this important drug discovery target. Herein we report on the first fully validated WHSC1 inhibitor, PTD2, a norleucine-containing peptide derived from the histone H4 sequence. This peptide exhibits micromolar affinity towards WHSC1 in biochemical and biophysical assays. Furthermore, a crystal structure was solved with the peptide in complex with SAM and the SET domain of WHSC1L1. This inhibitor is an important first step in creating potent, selective WHSC1 tool compounds for the purposes of understanding the complex biology in relation to human disease.
Collapse
Affiliation(s)
| | | | | | - Tim J. Wigle
- Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Dipti Sadalge
- Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Kevin W. Kuntz
- Epizyme Inc., Cambridge, Massachusetts, United States of America
| | | | | | | | | | - Darren M. Harvey
- Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - John W. Lampe
- Epizyme Inc., Cambridge, Massachusetts, United States of America
| | | | | |
Collapse
|
12
|
Mitchell LH, Boriack-Sjodin PA, Smith S, Thomenius M, Rioux N, Munchhof M, Mills JE, Klaus C, Totman J, Riera TV, Raimondi A, Jacques SL, West K, Foley M, Waters NJ, Kuntz KW, Wigle TJ, Scott MP, Copeland RA, Smith JJ, Chesworth R. Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor. ACS Med Chem Lett 2016; 7:134-8. [PMID: 26985287 DOI: 10.1021/acsmedchemlett.5b00272] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Accepted: 08/27/2015] [Indexed: 01/03/2023] Open
Abstract
SMYD3 has been implicated in a range of cancers; however, until now no potent selective small molecule inhibitors have been available for target validation studies. A novel oxindole series of SMYD3 inhibitors was identified through screening of the Epizyme proprietary histone methyltransferase-biased library. Potency optimization afforded two tool compounds, sulfonamide EPZ031686 and sulfamide EPZ030456, with cellular potency at a level sufficient to probe the in vitro biology of SMYD3 inhibition. EPZ031686 shows good bioavailability following oral dosing in mice making it a suitable tool for potential in vivo target validation studies.
Collapse
Affiliation(s)
- Lorna H. Mitchell
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - P. Ann Boriack-Sjodin
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Sherri Smith
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Michael Thomenius
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Nathalie Rioux
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Michael Munchhof
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - James E. Mills
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Christine Klaus
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Jennifer Totman
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Thomas V. Riera
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Alejandra Raimondi
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Suzanne L. Jacques
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Kip West
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Megan Foley
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Nigel J. Waters
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Kevin W. Kuntz
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Tim J. Wigle
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Margaret Porter Scott
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Robert A. Copeland
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Jesse J. Smith
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Richard Chesworth
- Epizyme Inc., Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
13
|
Basavapathruni A, Gureasko J, Porter Scott M, Hermans W, Godbole A, Leland PA, Boriack-Sjodin PA, Wigle TJ, Copeland RA, Riera TV. Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP. Biochemistry 2016; 55:1645-51. [PMID: 26813693 DOI: 10.1021/acs.biochem.5b01202] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The protein methyltransferase (PMT) SETDB1 is a strong candidate oncogene in melanoma and lung carcinomas. SETDB1 methylates lysine 9 of histone 3 (H3K9), utilizing S-adenosylmethionine (SAM) as the methyl donor and its catalytic activity, has been reported to be regulated by a partner protein ATF7IP. Here, we examine the contribution of ATF7IP to the in vitro activity and substrate specificity of SETDB1. SETDB1 and ATF7IP were co-expressed and 1:1 stoichiometric complexes were purified for comparison against SETDB1 enzyme alone. We employed both radiometric flashplate-based and SAMDI mass spectrometry assays to follow methylation on histone H3 15-mer peptides, where lysine 9 was either unmodified, monomethylated, or dimethylated. Results show that SETDB1 and the SETDB1:ATF7IP complex efficiently catalyze both monomethylation and dimethylation of H3K9 peptide substrates. The activity of the binary complex was 4-fold lower than SETDB1 alone. This difference was due to a decrease in the value of kcat as the substrate KM values were comparable between SETDB1 and the SETDB1:ATF7IP complex. H3K9 methylation by SETDB1 occurred in a distributive manner, and this too was unaffected by the presence of ATF7IP. This finding is important as H3K9 can be methylated by HMTs other than SETDB1 and a distributive mechanism would allow for interplay between multiple HMTs on H3K9. Our results indicate that ATF7IP does not directly modulate SETDB1 catalytic activity, suggesting alternate roles, such as affecting cellular localization or mediating interaction with additional binding partners.
Collapse
Affiliation(s)
| | - Jodi Gureasko
- Epizyme, Inc., 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | | | - William Hermans
- Blue Sky BioServices, Worcester, Massachusetts 01605, United States
| | | | | | - P Ann Boriack-Sjodin
- Epizyme, Inc., 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Tim J Wigle
- Epizyme, Inc., 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Robert A Copeland
- Epizyme, Inc., 400 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Thomas V Riera
- Epizyme, Inc., 400 Technology Square, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
14
|
Kuntz KW, Campbell JE, Keilhack H, Pollock RM, Knutson SK, Porter-Scott M, Richon VM, Sneeringer CJ, Wigle TJ, Allain CJ, Majer CR, Moyer MP, Copeland RA, Chesworth R. The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat. J Med Chem 2016; 59:1556-64. [DOI: 10.1021/acs.jmedchem.5b01501] [Citation(s) in RCA: 95] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Kevin W. Kuntz
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - John E. Campbell
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Heike Keilhack
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Roy M. Pollock
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Sarah K. Knutson
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Margaret Porter-Scott
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Victoria M. Richon
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Chris J. Sneeringer
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Tim J. Wigle
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Christina J. Allain
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Christina R. Majer
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Mikel P. Moyer
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Robert A. Copeland
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Richard Chesworth
- Epizyme, 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
15
|
Abstract
Understanding inhibitor binding modes is a key aspect of drug development. Early in a drug discovery effort these considerations often impact hit finding strategies and hit prioritization. Multiple inhibitor experiments, where enzyme inhibition is measured in the presence of two simultaneously varied inhibitors, can provide valuable information about inhibitor binding. These experiments utilize the inhibitor concentration dependence of the observed combined inhibition to determine the relationship between two compounds. In this way, it can be determined whether two inhibitors bind exclusively, independently, synergistically, or antagonistically. Novel inhibitors can be tested against each other or reference compounds to assist hit classification and characterization of inhibitor binding. In this chapter, we discuss the utility and design of multiple inhibitor experiments and present a new local curve fitting method for analyzing these data utilizing IC50 replots. The IC50 replot method is analogous to that used for determining mechanisms of inhibition with respect to substrate, as originally proposed by Cheng and Prusoff (Cheng and Prusoff Biochem Pharmacol 22: 3099-3108, 1973). The IC50 replot generated by this method reveals distinct patterns that are diagnostic of the nature of the interaction between two inhibitors. Multiple inhibition of the histone methyltransferase EZH2 by EPZ-5687 and the reaction product S-adenosylhomocysteine is presented as an example of the method.
Collapse
Affiliation(s)
- Thomas V Riera
- Epizyme, Inc., 4th Floor, 400 Technology Square, Cambridge, MA, 02139, USA.
| | - Tim J Wigle
- Ribon Therapeutics, 99 Hayden Ave., Building D, Suite 100, Lexington, MA, 02421, USA
| | - Robert A Copeland
- Epizyme, Inc., 4th Floor, 400 Technology Square, Cambridge, MA, 02139, USA
| |
Collapse
|
16
|
Mitchell LH, Boriack-Sjodin PA, Smith S, Thomenius M, Rioux N, Munchhof M, Mills JE, Klaus C, Totman J, Riera TV, Raimondi A, Jacques SL, Foley M, Waters NJ, Kuntz KW, Wigle TJ, Porter Scott M, Copeland RA, Smith JJ, Chesworth R. Abstract C85: Identification of a novel potent selective SMYD3 inhibitor with oral bioavailability. Mol Cancer Ther 2015. [DOI: 10.1158/1535-7163.targ-15-c85] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
SMYD3 (Set and Mynd Domain containing 3) is a lysine methyltransferase overexpressed in several cancer types including breast, prostrate, pancreatic, and lung, and this overexpression is associated with poor clinical prognosis. Genetic knockdown of SMYD3 by shRNA has been shown to decrease proliferation in a range of cancer cell lines suggesting that inhibition of SMYD3 may have therapeutic utility.
In this presentation we describe the discovery and optimization of a novel series of oxindole sulfonamides and sulfamides with SMYD3 inhibitory activity. One of these compounds, EPZ030456, has a SMYD3 biochemical IC50 of 4 nM and is active in cells with an IC50 of 48 nM in a trimethyl MAP3K2 (MEKK2) in-cell western (ICW) assay. The crystal structure of this compound was solved with SMYD3 and the nucleotide substrate, S-adenosylmethionine and shows the oxindole portion of the molecule extends into the SMYD3 lysine binding channel. EPZ030456 shows < 30% inhibition at a 10 uM screening concentration against 17 histone methyltransferase targets tested, including SMYD2.
Further optimization within the series resulted in EPZ031686 which has similar potency to EPZ030456 with a biochemical IC50 of 3 nM and an ICW IC50 of 36 nM and in addition exhibits good bioavailability following oral dosing in mice. Hence, EPZ031686 is a suitable tool to study the role of SMYD3 in cancer and other therapeutic areas, using both in vitro and in vivo models.
Citation Format: Lorna H. Mitchell, Paula A. Boriack-Sjodin, Sherri Smith, Michael Thomenius, Nathalie Rioux, Michael Munchhof, James E. Mills, Christine Klaus, Jennifer Totman, Thomas V. Riera, Alejandra Raimondi, Suzanne L. Jacques, Megan Foley, Nigel J. Waters, Kevin W. Kuntz, Tim J. Wigle, Margaret Porter Scott, Robert A. Copeland, Jesse J. Smith, Richard Chesworth. Identification of a novel potent selective SMYD3 inhibitor with oral bioavailability. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C85.
Collapse
|
17
|
Riera TV, Wigle TJ, Gureasko J, Boriack-Sjodin PA, Copeland RA. Abstract 2144: Kinetic mechanism of the lysine methyltransferase SMYD3 using MAP3K2 protein substrate. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-2144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Dysregulation of DNA and histone methylation has been shown to play fundamental roles in carcinogenesis. Recently however, protein methylation in the cytoplasm has been linked to oncogenic Ras signaling. Mazur and colleagues demonstrated that SMYD3 (SET and MYND domain containing protein 3), a primarily cytoplasmic protein methyltransferase, can methylate MAP3K2 using S-adenosyl-L-methionine (SAM) as a cofactor (Mazur et al. 2014. Nature 510(7504):283-7). Methylation by SMYD3 preserves the active, phosphorylated state of MAP3K2 sustaining activation of the Ras/Raf/MEK/ERK/ signaling module and potentiating formation of Ras-driven cancers. Here, we characterized the kinetic mechanism of SMYD3 using MAP3K2 protein as a substrate. SMYD3 activity was measured with a radiometric assay using 3H-SAM. Initial velocity, product and dead-end inhibitor studies indicate that SMYD3 uses a random kinetic mechanism where both SAM and MAP3K2 can bind apo-SMYD3. This was supported by substrate and ligand binding assays using SPR. Together, these studies elucidate the kinetic mechanism of SMYD3 with MAP3K2 and provide a context for inhibitor development.
Citation Format: Thomas V. Riera, Tim J. Wigle, Jodi Gureasko, P. Ann Boriack-Sjodin, Robert A. Copeland. Kinetic mechanism of the lysine methyltransferase SMYD3 using MAP3K2 protein substrate. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2144. doi:10.1158/1538-7445.AM2015-2144
Collapse
|
18
|
Mitchell LH, Drew AE, Ribich SA, Rioux N, Swinger KK, Jacques SL, Lingaraj T, Boriack-Sjodin PA, Waters NJ, Wigle TJ, Moradei O, Jin L, Riera T, Porter-Scott M, Moyer MP, Smith JJ, Chesworth R, Copeland RA. Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Med Chem Lett 2015; 6:655-9. [PMID: 26101569 DOI: 10.1021/acsmedchemlett.5b00071] [Citation(s) in RCA: 92] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 04/06/2015] [Indexed: 01/27/2023] Open
Abstract
A novel aryl pyrazole series of arginine methyltransferase inhibitors has been identified. Synthesis of analogues within this series yielded the first potent, selective, small molecule PRMT6 inhibitor tool compound, EPZ020411. PRMT6 overexpression has been reported in several cancer types suggesting that inhibition of PRMT6 activity may have therapeutic utility. Identification of EPZ020411 provides the field with the first small molecule tool compound for target validation studies. EPZ020411 shows good bioavailability following subcutaneous dosing in rats making it a suitable tool for in vivo studies.
Collapse
Affiliation(s)
- Lorna H. Mitchell
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Allison E. Drew
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Scott A. Ribich
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Nathalie Rioux
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Kerren K. Swinger
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Suzanne L. Jacques
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Trupti Lingaraj
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - P. Ann Boriack-Sjodin
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Nigel J. Waters
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Tim J. Wigle
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Oscar Moradei
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Lei Jin
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Tom Riera
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Margaret Porter-Scott
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Mikel P. Moyer
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Jesse J. Smith
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Richard Chesworth
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| | - Robert A. Copeland
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02138, United States
| |
Collapse
|
19
|
Campbell JE, Kuntz KW, Knutson SK, Warholic NM, Keilhack H, Wigle TJ, Raimondi A, Klaus CR, Rioux N, Yokoi A, Kawano S, Minoshima Y, Choi HW, Porter Scott M, Waters NJ, Smith JJ, Chesworth R, Moyer MP, Copeland RA. EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Med Chem Lett 2015; 6:491-5. [PMID: 26005520 PMCID: PMC4434464 DOI: 10.1021/acsmedchemlett.5b00037] [Citation(s) in RCA: 91] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2015] [Accepted: 03/04/2015] [Indexed: 12/17/2022] Open
Abstract
![]()
Inhibitors
of the protein methyltransferase Enhancer of Zeste Homolog 2 (EZH2)
may have significant therapeutic potential for the treatment of B
cell lymphomas and other cancer indications. The ability of the scientific
community to explore fully the spectrum of EZH2-associated pathobiology
has been hampered by the lack of in vivo-active tool compounds for
this enzyme. Here we report the discovery and characterization of EPZ011989, a potent, selective, orally bioavailable inhibitor
of EZH2 with useful pharmacokinetic properties. EPZ011989 demonstrates significant tumor growth inhibition in a mouse xenograft
model of human B cell lymphoma. Hence, this compound represents a
powerful tool for the expanded exploration of EZH2 activity in biology.
Collapse
Affiliation(s)
- John E. Campbell
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Kevin W. Kuntz
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Sarah K. Knutson
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Natalie M. Warholic
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Heike Keilhack
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Tim J. Wigle
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Alejandra Raimondi
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Christine R. Klaus
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Nathalie Rioux
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Akira Yokoi
- Eisai Co., Ltd., Tokodai 5-1-3, Tsukuba, Ibarakai 300-2635, Japan
| | - Satoshi Kawano
- Eisai Co., Ltd., Tokodai 5-1-3, Tsukuba, Ibarakai 300-2635, Japan
| | | | - Hyeong-Wook Choi
- Eisai, Inc., 4 Corporate Drive, Andover, Massachusetts 01810, United States
| | - Margaret Porter Scott
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Nigel J. Waters
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Jesse J. Smith
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Richard Chesworth
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Mikel P. Moyer
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Robert A. Copeland
- Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
20
|
Wigle TJ, Swinger KK, Campbell JE, Scholle MD, Sherrill J, Admirand EA, Boriack-Sjodin PA, Kuntz KW, Chesworth R, Moyer MP, Scott MP, Copeland RA. A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening. ACTA ACUST UNITED AC 2015; 20:810-20. [DOI: 10.1177/1087057115575689] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Accepted: 02/06/2015] [Indexed: 11/17/2022]
Abstract
Demethylation of histones by lysine demethylases (KDMs) plays a critical role in controlling gene transcription. Aberrant demethylation may play a causal role in diseases such as cancer. Despite the biological significance of these enzymes, there are limited assay technologies for study of KDMs and few quality chemical probes available to interrogate their biology. In this report, we demonstrate the utility of self-assembled monolayer desorption/ionization (SAMDI) mass spectrometry for the investigation of quantitative KDM enzyme kinetics and for high-throughput screening for KDM inhibitors. SAMDI can be performed in 384-well format and rapidly allows reaction components to be purified prior to injection into a mass spectrometer, without a throughput-limiting liquid chromatography step. We developed sensitive and robust assays for KDM1A (LSD1, AOF2) and KDM4C (JMJD2C, GASC1) and screened 13,824 compounds against each enzyme. Hits were rapidly triaged using a redox assay to identify compounds that interfered with the catalytic oxidation chemistry used by the KDMs for the demethylation reaction. We find that overall this high-throughput mass spectrometry platform coupled with the elimination of redox active compounds leads to a hit rate that is manageable for follow-up work.
Collapse
|
21
|
Knutson SK, Warholic NM, Johnston LD, Klaus CR, Wigle TJ, Iwanowicz D, Littlefield BA, Porter-Scott M, Smith JJ, Moyer MP, Copeland RA, Pollock RM, Kuntz KW, Raimondi A, Keilhack H. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. PLoS One 2014; 9:e111840. [PMID: 25493630 PMCID: PMC4262195 DOI: 10.1371/journal.pone.0111840] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2014] [Accepted: 10/01/2014] [Indexed: 01/07/2023] Open
Abstract
Patients with non-Hodgkin lymphoma (NHL) are treated today with a cocktail of drugs referred to as CHOP (Cyclophosphamide, Hydroxyldaunorubicin, Oncovin, and Prednisone). Subsets of patients with NHL of germinal center origin bear oncogenic mutations in the EZH2 histone methyltransferase. Clinical testing of the EZH2 inhibitor EPZ-6438 has recently begun in patients. We report here that combining EPZ-6438 with CHOP in preclinical cell culture and mouse models results in dramatic synergy for cell killing in EZH2 mutant germinal center NHL cells. Surprisingly, we observe that much of this synergy is due to Prednisolone - a glucocorticoid receptor agonist (GRag) component of CHOP. Dramatic synergy was observed when EPZ-6438 is combined with Prednisolone alone, and a similar effect was observed with Dexamethasone, another GRag. Remarkably, the anti-proliferative effect of the EPZ-6438+GRag combination extends beyond EZH2 mutant-bearing cells to more generally impact germinal center NHL. These preclinical data reveal an unanticipated biological intersection between GR-mediated gene regulation and EZH2-mediated chromatin remodeling. The data also suggest the possibility of a significant and practical benefit of combining EZH2 inhibitors and GRag that warrants further investigation in a clinical setting.
Collapse
Affiliation(s)
- Sarah K. Knutson
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Natalie M. Warholic
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - L. Danielle Johnston
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Christine R. Klaus
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Tim J. Wigle
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Dorothy Iwanowicz
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | | | - Margaret Porter-Scott
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Jesse J. Smith
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Mikel P. Moyer
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Robert A. Copeland
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Roy M. Pollock
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Kevin W. Kuntz
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Alejandra Raimondi
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| | - Heike Keilhack
- Research and Development, Epizyme Inc., Cambridge, Massachusetts, United States of America
| |
Collapse
|
22
|
Swalm BM, Knutson SK, Warholic NM, Jin L, Kuntz KW, Keilhack H, Smith JJ, Pollock RM, Moyer MP, Scott MP, Copeland RA, Wigle TJ. Reaction coupling between wild-type and disease-associated mutant EZH2. ACS Chem Biol 2014; 9:2459-64. [PMID: 25154026 DOI: 10.1021/cb500548b] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
EZH2 and EZH1 are protein methyltransferases (PMTs) responsible for histone H3, lysine 27 (H3K27) methylation. Trimethylation of H3K27 (H3K27me3) is a hallmark of many cancers, including non-Hodgkin lymphoma (NHL). Heterozygous EZH2 point mutations at Tyr641, Ala677, and Ala687 have been observed in NHL. The Tyr641 mutations enhance activity on H3K27me2 but have weak or no activity on unmethylated H3K27, whereas the Ala677 and Ala687 mutations use substrates of all methylation states effectively. It has been proposed that enzymatic coupling of the wild-type and mutant enzymes leads to the oncogenic H3K27me3 mark in mutant-bearing NHL. We show that coupling with the wild-type enzyme is needed to achieve H3K27me3 for several mutants, but that others are capable of achieving H3K27me3 on their own. All forms of PRC2 (wild-type and mutants) display kinetic signatures that are consistent with a distributive mechanism of catalysis.
Collapse
Affiliation(s)
- Brooke M. Swalm
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Sarah K. Knutson
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Natalie M. Warholic
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Lei Jin
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Kevin W. Kuntz
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Heike Keilhack
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Jesse J. Smith
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Roy M. Pollock
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Mikel P. Moyer
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Margaret Porter Scott
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Robert A. Copeland
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| | - Tim J. Wigle
- Epizyme, Inc. 400 Technology Square,
Fourth Floor, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
23
|
Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, Kadowaki T, Uesugi M, Kuznetsov G, Kumar N, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Waters NJ, Smith JJ, Porter-Scott M, Chesworth R, Moyer MP, Copeland RA, Richon VM, Uenaka T, Pollock RM, Kuntz KW, Yokoi A, Keilhack H. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014; 13:842-54. [PMID: 24563539 DOI: 10.1158/1535-7163.mct-13-0773] [Citation(s) in RCA: 400] [Impact Index Per Article: 40.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Mutations within the catalytic domain of the histone methyltransferase EZH2 have been identified in subsets of patients with non-Hodgkin lymphoma (NHL). These genetic alterations are hypothesized to confer an oncogenic dependency on EZH2 enzymatic activity in these cancers. We have previously reported the discovery of EPZ005678 and EPZ-6438, potent and selective S-adenosyl-methionine-competitive small molecule inhibitors of EZH2. Although both compounds are similar with respect to their mechanism of action and selectivity, EPZ-6438 possesses superior potency and drug-like properties, including good oral bioavailability in animals. Here, we characterize the activity of EPZ-6438 in preclinical models of NHL. EPZ-6438 selectively inhibits intracellular lysine 27 of histone H3 (H3K27) methylation in a concentration- and time-dependent manner in both EZH2 wild-type and mutant lymphoma cells. Inhibition of H3K27 trimethylation (H3K27Me3) leads to selective cell killing of human lymphoma cell lines bearing EZH2 catalytic domain point mutations. Treatment of EZH2-mutant NHL xenograft-bearing mice with EPZ-6438 causes dose-dependent tumor growth inhibition, including complete and sustained tumor regressions with correlative diminution of H3K27Me3 levels in tumors and selected normal tissues. Mice dosed orally with EPZ-6438 for 28 days remained tumor free for up to 63 days after stopping compound treatment in two EZH2-mutant xenograft models. These data confirm the dependency of EZH2-mutant NHL on EZH2 activity and portend the utility of EPZ-6438 as a potential treatment for these genetically defined cancers.
Collapse
Affiliation(s)
- Sarah K Knutson
- Authors' Affiliations: Epizyme Inc., Cambridge; Eisai Inc., Andover, Massachusetts; and Eisai Co. Ltd., Tsukuba-shi, Ibaraki, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Wigle TJ, Copeland RA. Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription. Curr Opin Chem Biol 2013; 17:369-78. [PMID: 23619004 DOI: 10.1016/j.cbpa.2013.03.035] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2012] [Accepted: 03/28/2013] [Indexed: 01/16/2023]
Abstract
Protein and DNA methylation have emerged as critical mechanisms for the control of regulated gene transcription. In humans, the addition, recognition and removal of methyl groups are orchestrated by at least 344 proteins that we collectively refer to as the 'methylome'. The large size of the methylome likely reflects the importance of precise control over this small covalent modification. An increasing number of reports implicating the misregulation of methylation in disease make the proteins governing this modification attractive target for small molecule drug discovery. In light of the emerging opportunities for the development of therapeutics that modulate methylation-dependent pathways, this review examines the protein families that constitute the methylome, with emphasis on the methylation of arginine and lysine residues of proteins. Genetic aberrations that give rise to disease are highlighted, in addition to recent proof-of-concept successes in the development of small molecule modulators of methylome constituents.
Collapse
Affiliation(s)
- Tim J Wigle
- Epizyme Inc., 400 Technology Square, 4th Floor, Cambridge, MA 02139, United States
| | | |
Collapse
|
25
|
Basavapathruni A, Jin L, Daigle SR, Majer CRA, Therkelsen CA, Wigle TJ, Kuntz KW, Chesworth R, Pollock RM, Scott MP, Moyer MP, Richon VM, Copeland RA, Olhava EJ. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des 2012; 80:971-80. [PMID: 22978415 DOI: 10.1111/cbdd.12050] [Citation(s) in RCA: 107] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
DOT1L is the human protein methyltransferase responsible for catalyzing the methylation of histone H3 on lysine 79 (H3K79). The ectopic activity of DOT1L, associated with the chromosomal translocation that is a universal hallmark of MLL-rearranged leukemia, is a required driver of leukemogenesis in this malignancy. Here, we present studies on the structure-activity relationship of aminonucleoside-based DOT1L inhibitors. Within this series, we find that improvements in target enzyme affinity and selectivity are driven entirely by diminution of the dissociation rate constant for the enzyme-inhibitor complex, leading to long residence times for the binary complex. The biochemical K(i) and residence times measured for these inhibitors correlate well with their effects on intracellular H3K79 methylation and MLL-rearranged leukemic cell killing. Crystallographic studies reveal a conformational adaptation mechanism associated with high-affinity inhibitor binding and prolonged residence time; these studies also suggest that conformational adaptation likewise plays a critical role in natural ligand interactions with the enzyme, hence, facilitating enzyme turnover. These results provide critical insights into the role of conformational adaptation in the enzymatic mechanism of catalysis and in pharmacologic intervention for DOT1L and other members of this enzyme class.
Collapse
|
26
|
Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, Moyer MP, Richon VM, Copeland RA, Keilhack H, Pollock RM, Kuntz KW. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8:890-6. [PMID: 23023262 DOI: 10.1038/nchembio.1084] [Citation(s) in RCA: 603] [Impact Index Per Article: 50.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2012] [Accepted: 07/13/2012] [Indexed: 12/24/2022]
Abstract
EZH2 catalyzes trimethylation of histone H3 lysine 27 (H3K27). Point mutations of EZH2 at Tyr641 and Ala677 occur in subpopulations of non-Hodgkin's lymphoma, where they drive H3K27 hypertrimethylation. Here we report the discovery of EPZ005687, a potent inhibitor of EZH2 (K(i) of 24 nM). EPZ005687 has greater than 500-fold selectivity against 15 other protein methyltransferases and has 50-fold selectivity against the closely related enzyme EZH1. The compound reduces H3K27 methylation in various lymphoma cells; this translates into apoptotic cell killing in heterozygous Tyr641 or Ala677 mutant cells, with minimal effects on the proliferation of wild-type cells. These data suggest that genetic alteration of EZH2 (for example, mutations at Tyr641 or Ala677) results in a critical dependency on enzymatic activity for proliferation (that is, the equivalent of oncogene addiction), thus portending the clinical use of EZH2 inhibitors for cancers in which EZH2 is genetically altered.
Collapse
|
27
|
Majer CR, Jin L, Scott MP, Knutson SK, Kuntz KW, Keilhack H, Smith JJ, Moyer MP, Richon VM, Copeland RA, Wigle TJ. A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett 2012; 586:3448-51. [PMID: 22850114 DOI: 10.1016/j.febslet.2012.07.066] [Citation(s) in RCA: 111] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2012] [Revised: 07/18/2012] [Accepted: 07/19/2012] [Indexed: 01/12/2023]
Abstract
Heterozygous point mutations at Y641 and A677 in the EZH2 SET domain are prevalent in about 10-24% of Non-Hodgkin lymphomas (NHL). Previous studies indicate that these are gain-of-function mutations leading to the hypertrimethylation of H3K27. These EZH2 mutations may drive the proliferation of lymphoma and make EZH2 a molecular target for patients harboring these mutations. Here, another EZH2 SET domain point mutation, A687V, occurring in about 1-2% of lymphoma patients, is also shown to be a gain-of-function mutation that greatly enhances its ability to perform dimethylation relative to wild-type EZH2 and is equally proficient at catalyzing trimethylation. We propose that A687V EZH2 also leads to hypertrimethylation of H3K27 and may thus be a driver mutation in NHL.
Collapse
|
28
|
Affiliation(s)
- Tim J Wigle
- Epizyme, 840 Memorial Drive, Cambridge, MA 02139, USA
| |
Collapse
|
29
|
Wigle TJ, Knutson SK, Jin L, Kuntz KW, Pollock RM, Richon VM, Copeland RA, Scott MP. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett 2011; 585:3011-4. [PMID: 21856302 DOI: 10.1016/j.febslet.2011.08.018] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2011] [Revised: 08/05/2011] [Accepted: 08/09/2011] [Indexed: 10/17/2022]
Abstract
Mutations at tyrosine 641 (Y641F, Y641N, Y641S and Y641H) in the SET domain of EZH2 have been identified in patients with certain subtypes of non-Hodgkin lymphoma (NHL). These mutations were shown to change the substrate specificity of EZH2 for various methylation states of lysine 27 on histone H3 (H3K27). An additional mutation at EZH2 Y641 to cysteine (Y641C) was also found in one patient with NHL and in SKM-1 cells derived from a patient with myelodisplastic syndrome (MDS). The Y641C mutation has been reported to dramatically reduce enzymatic activity. Here, we demonstrate that while the Y641C mutation ablates enzymatic activity against unmethylated and monomethylated H3K27, it is superior to wild-type in catalyzing the formation of trimethylated H3K27 from the dimethylated precursor.
Collapse
Affiliation(s)
- Tim J Wigle
- Epizyme, Inc., 325 Vassar St., Cambridge, MA 02139, USA.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, Wigle TJ, Dimaggio PA, Wasney GA, Siarheyeva A, Dong A, Tempel W, Wang SC, Chen X, Chau I, Mangano TJ, Huang XP, Simpson CD, Pattenden SG, Norris JL, Kireev DB, Tripathy A, Edwards A, Roth BL, Janzen WP, Garcia BA, Petronis A, Ellis J, Brown PJ, Frye SV, Arrowsmith CH, Jin J. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 2011; 7:566-74. [PMID: 21743462 DOI: 10.1038/nchembio.599] [Citation(s) in RCA: 400] [Impact Index Per Article: 30.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2010] [Accepted: 04/27/2011] [Indexed: 12/12/2022]
Abstract
Protein lysine methyltransferases G9a and GLP modulate the transcriptional repression of a variety of genes via dimethylation of Lys9 on histone H3 (H3K9me2) as well as dimethylation of non-histone targets. Here we report the discovery of UNC0638, an inhibitor of G9a and GLP with excellent potency and selectivity over a wide range of epigenetic and non-epigenetic targets. UNC0638 treatment of a variety of cell lines resulted in lower global H3K9me2 levels, equivalent to levels observed for small hairpin RNA knockdown of G9a and GLP with the functional potency of UNC0638 being well separated from its toxicity. UNC0638 markedly reduced the clonogenicity of MCF7 cells, reduced the abundance of H3K9me2 marks at promoters of known G9a-regulated endogenous genes and disproportionately affected several genomic loci encoding microRNAs. In mouse embryonic stem cells, UNC0638 reactivated G9a-silenced genes and a retroviral reporter gene in a concentration-dependent manner without promoting differentiation.
Collapse
Affiliation(s)
- Masoud Vedadi
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Herold JM, Wigle TJ, Norris JL, Lam R, Korboukh VK, Gao C, Ingerman LA, Kireev DB, Senisterra G, Vedadi M, Tripathy A, Brown PJ, Arrowsmith CH, Jin J, Janzen WP, Frye SV. Small-molecule ligands of methyl-lysine binding proteins. J Med Chem 2011; 54:2504-11. [PMID: 21417280 PMCID: PMC3109722 DOI: 10.1021/jm200045v] [Citation(s) in RCA: 104] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Proteins which bind methylated lysines ("readers" of the histone code) are important components in the epigenetic regulation of gene expression and can also modulate other proteins that contain methyl-lysine such as p53 and Rb. Recognition of methyl-lysine marks by MBT domains leads to compaction of chromatin and a repressed transcriptional state. Antagonists of MBT domains would serve as probes to interrogate the functional role of these proteins and initiate the chemical biology of methyl-lysine readers as a target class. Small-molecule MBT antagonists were designed based on the structure of histone peptide-MBT complexes and their interaction with MBT domains determined using a chemiluminescent assay and ITC. The ligands discovered antagonize native histone peptide binding, exhibiting 5-fold stronger binding affinity to L3MBTL1 than its preferred histone peptide. The first cocrystal structure of a small molecule bound to L3MBTL1 was determined and provides new insights into binding requirements for further ligand design.
Collapse
Affiliation(s)
- J. Martin Herold
- Center for Integrated Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill Chapel Hill, North Carolina 27599, USA
| | - Tim J. Wigle
- Center for Integrated Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill Chapel Hill, North Carolina 27599, USA
| | - Jacqueline L. Norris
- Center for Integrated Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill Chapel Hill, North Carolina 27599, USA
| | - Robert Lam
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Ontario, Canada
| | - Victoria K. Korboukh
- Center for Integrated Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill Chapel Hill, North Carolina 27599, USA
| | - Cen Gao
- Center for Integrated Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill Chapel Hill, North Carolina 27599, USA
| | - Lindsey A. Ingerman
- Center for Integrated Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill Chapel Hill, North Carolina 27599, USA
| | - Dmitri B. Kireev
- Center for Integrated Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill Chapel Hill, North Carolina 27599, USA
| | - Guillermo Senisterra
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Ontario, Canada
| | - Masoud Vedadi
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Ontario, Canada
| | - Ashutosh Tripathy
- Department of Biochemistry and Biophysics, UNC Macromolecular Interactions Facility, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Peter J. Brown
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Ontario, Canada
| | - Cheryl H. Arrowsmith
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Ontario, Canada
| | - Jian Jin
- Center for Integrated Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill Chapel Hill, North Carolina 27599, USA
| | - William P. Janzen
- Center for Integrated Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill Chapel Hill, North Carolina 27599, USA
| | - Stephen V. Frye
- Center for Integrated Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill Chapel Hill, North Carolina 27599, USA
| |
Collapse
|
32
|
Kireev D, Wigle TJ, Norris-Drouin J, Herold JM, Janzen WP, Frye SV. Identification of non-peptide malignant brain tumor (MBT) repeat antagonists by virtual screening of commercially available compounds. J Med Chem 2010; 53:7625-31. [PMID: 20931980 DOI: 10.1021/jm1007374] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The malignant brain tumor (MBT) repeat is an important epigenetic-code "reader" and is functionally associated with differentiation, gene silencing, and tumor suppression. (1-3) Small molecule probes of MBT domains should enable a systematic study of MBT-containing proteins and potentially reveal novel druggable targets. We designed and applied a virtual screening strategy that identified potential MBT antagonists in a large database of commercially available compounds. A small set of virtual hits was purchased and submitted to experimental testing. Nineteen of the purchased compounds showed a specific dose-dependent protein binding and will provide critical structure-activity information for subsequent lead generation and optimization.
Collapse
Affiliation(s)
- Dmitri Kireev
- Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina 27599-7363, United States.
| | | | | | | | | | | |
Collapse
|
33
|
Wigle TJ, Provencher LM, Norris JL, Jin J, Brown PJ, Frye SV, Janzen WP. Accessing protein methyltransferase and demethylase enzymology using microfluidic capillary electrophoresis. ACTA ACUST UNITED AC 2010; 17:695-704. [PMID: 20659682 DOI: 10.1016/j.chembiol.2010.04.014] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2010] [Revised: 04/08/2010] [Accepted: 04/16/2010] [Indexed: 12/11/2022]
Abstract
The discovery of small molecules targeting the >80 enzymes that add (methyltransferases) or remove (demethylases) methyl marks from lysine and arginine residues, most notably present in histone tails, may yield unprecedented chemotherapeutic agents and facilitate regenerative medicine. To better enable chemical exploration of these proteins, we have developed a highly quantitative microfluidic capillary electrophoresis assay to enable full mechanistic studies of these enzymes and the kinetics of their inhibition. This technology separates small biomolecules, i.e., peptides, based on their charge-to-mass ratio. Methylation, however, does not alter the charge of peptide substrates. To overcome this limitation, we have employed a methylation-sensitive endoproteinase strategy to separate methylated from unmethylated peptides. The assay was validated on a lysine methyltransferase (G9a) and a lysine demethylase (LSD1) and was employed to investigate the inhibition of G9a by small molecules.
Collapse
Affiliation(s)
- Tim J Wigle
- Center for Integrative Chemical Biology and Drug Discovery Division of Medicinal Chemistry and Natural Products, Eshelman School of Pharmacy, The University of North Carolina, CB #7363, 120 Mason Farm Road, Chapel Hill, NC 27599-7363, USA
| | | | | | | | | | | | | |
Collapse
|
34
|
Liu F, Chen X, Allali-Hassani A, Quinn AM, Wigle TJ, Wasney GA, Dong A, Senisterra G, Chau I, Siarheyeva A, Norris JL, Kireev DB, Jadhav A, Herold JM, Janzen WP, Arrowsmith CH, Frye SV, Brown PJ, Simeonov A, Vedadi M, Jin J. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem 2010; 53:5844-57. [PMID: 20614940 DOI: 10.1021/jm100478y] [Citation(s) in RCA: 151] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Protein lysine methyltransferase G9a, which catalyzes methylation of lysine 9 of histone H3 (H3K9) and lysine 373 (K373) of p53, is overexpressed in human cancers. Genetic knockdown of G9a inhibits cancer cell growth, and the dimethylation of p53 K373 results in the inactivation of p53. Initial SAR exploration of the 2,4-diamino-6,7-dimethoxyquinazoline template represented by 3a (BIX01294), a selective small molecule inhibitor of G9a and GLP, led to the discovery of 10 (UNC0224) as a potent G9a inhibitor with excellent selectivity. A high resolution X-ray crystal structure of the G9a-10 complex, the first cocrystal structure of G9a with a small molecule inhibitor, was obtained. On the basis of the structural insights revealed by this cocrystal structure, optimization of the 7-dimethylaminopropoxy side chain of 10 resulted in the discovery of 29 (UNC0321) (Morrison K(i) = 63 pM), which is the first G9a inhibitor with picomolar potency and the most potent G9a inhibitor to date.
Collapse
Affiliation(s)
- Feng Liu
- Center for Integrative Chemical Biology and Drug Discovery, Division of Medicinal Chemistry and Natural Products, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Sexton JZ, Wigle TJ, He Q, Hughes MA, Smith GR, Singleton SF, Williams AL, Yeh LA. Novel Inhibitors of E. coli RecA ATPase Activity. Curr Chem Genomics 2010; 4:34-42. [PMID: 20648224 PMCID: PMC2905775 DOI: 10.2174/1875397301004010034] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/23/2009] [Revised: 12/07/2009] [Accepted: 12/12/2009] [Indexed: 11/22/2022]
Abstract
The bacterial RecA protein has been implicated as a bacterial drug target not as an antimicrobial target, but as an adjuvant target with the potential to suppress the mechanism by which bacteria gain drug resistance. In order to identify small molecules that inhibit RecA/ssDNA nucleoprotein filament formation, we have adapted the phosphomolybdate-blue ATPase assay for high throughput screening to determine RecA ATPase activity against a library of 33,600 compounds, which is a selected representation of diverse structure of 350,000. Four distinct chemotypes were represented among the 40 validated hits. SAR and further chemical synthesis is underway to optimize this set of inhibitors to be used as antimicrobial adjuvant agents.
Collapse
Affiliation(s)
- Jonathan Z Sexton
- Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, 27707, USA
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Wigle TJ, Herold JM, Senisterra GA, Vedadi M, Kireev DB, Arrowsmith CH, Frye SV, Janzen WP. Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreen-based assay for antagonists of methyl-lysine binding proteins. ACTA ACUST UNITED AC 2009; 15:62-71. [PMID: 20008125 DOI: 10.1177/1087057109352902] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The histone code comprises many posttranslational modifications that occur mainly in histone tail peptides. The identity and location of these marks are read by a variety of histone-binding proteins that are emerging as important regulators of cellular differentiation and development and are increasingly being implicated in numerous disease states. The authors describe the development of the first high-throughput screening assay for the discovery of inhibitors of methyl-lysine binding proteins that will be used to initiate a full-scale discovery effort for this broad target class. They focus on the development of an AlphaScreen-based assay for malignant brain tumor (MBT) domain-containing proteins, which bind to the lower methylation states of lysine residues present in histone tail peptides. This assay takes advantage of the avidity of the AlphaScreen beads to clear the hurdle to assay development presented by the low micromolar binding constants of the histone binding proteins for their cognate peptides. The assay is applicable to other families of methyl-lysine binding proteins, and it has the potential to be used in screening efforts toward the discovery of novel small molecules with utility as research tools for cellular reprogramming and ultimately drug discovery.
Collapse
Affiliation(s)
- Tim J Wigle
- Center for Integrative Chemical Biology and Drug Discovery, Division of Medicinal Chemistry and Natural Products, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Wigle TJ, Sexton JZ, Gromova AV, Hadimani MB, Hughes MA, Smith GR, Yeh LA, Singleton SF. Inhibitors of RecA activity discovered by high-throughput screening: cell-permeable small molecules attenuate the SOS response in Escherichia coli. ACTA ACUST UNITED AC 2009; 14:1092-101. [PMID: 19675313 DOI: 10.1177/1087057109342126] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The phenomenon of antibiotic resistance has created a need for the development of novel antibiotic classes with nonclassical cellular targets. Unfortunately, target-based drug discovery against proteins considered essential for in vitro bacterial viability has yielded few new therapeutic classes of antibiotics. Targeting the large proportion of genes considered nonessential that have yet to be explored by high-throughput screening, for example, RecA, can complement these efforts. Recent evidence suggests that RecA-controlled processes are responsible for tolerance to antibiotic chemotherapy and are involved in pathways that ultimately lead to full-fledged antibiotic resistance. Therefore inhibitors of RecA may serve as therapeutic adjuvants in combination chemotherapy of bacterial infectious diseases. Toward the goal of validating RecA as a novel target in the chemotherapy of bacterial infections, the authors have screened 35,780 small molecules against RecA. In total, 80 small molecules were identified as primary hits and could be clustered in 6 distinct chemotype clades. The most potent class of hits was further examined, and 1 member compound was found to inhibit RecA-mediated strand exchange and prevent ciprofloxacin-induced SOS expression in Escherichia coli. This compound represents the first small molecule demonstrating an ability to inhibit the bacterial SOS response in live bacterial cell cultures.
Collapse
Affiliation(s)
- Tim J Wigle
- UNC Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7360, USA
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Lee AM, Wigle TJ, Singleton SF. A complementary pair of rapid molecular screening assays for RecA activities. Anal Biochem 2007; 367:247-58. [PMID: 17601483 PMCID: PMC2041836 DOI: 10.1016/j.ab.2007.04.021] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2007] [Revised: 04/04/2007] [Accepted: 04/17/2007] [Indexed: 11/23/2022]
Abstract
The bacterial RecA protein has been implicated in the evolution of antibiotic resistance in pathogens, which is an escalating problem worldwide. The discovery of small molecules that can selectively modulate RecA's activities can be exploited to tease apart its roles in the de novo development and transmission of antibiotic resistance genes. Toward the goal of discovering small-molecule ligands that can prevent either the assembly of an active RecA-DNA filament or its subsequent ATP-dependent motor activities, we report the design and initial validation of a pair of rapid and robust screening assays suitable for the identification of inhibitors of RecA activities. One assay is based on established methods for monitoring ATPase enzyme activity and the second is a novel assay for RecA-DNA filament assembly using fluorescence polarization. Taken together, the assay results reveal complementary sets of agents that can either suppress selectively only the ATP-driven motor activities of the RecA-DNA filament or prevent assembly of active RecA-DNA filaments altogether. The screening assays can be readily configured for use in future automated high-throughput screening projects to discover potent inhibitors that may be developed into novel adjuvants for antibiotic chemotherapy that moderate the development and transmission of antibiotic resistance genes and increase the antibiotic therapeutic index.
Collapse
Affiliation(s)
- Andrew M Lee
- Division of Medicinal Chemistry and Natural Products, School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360, USA
| | | | | |
Collapse
|
39
|
Wigle TJ, Singleton SF. Directed molecular screening for RecA ATPase inhibitors. Bioorg Med Chem Lett 2007; 17:3249-53. [PMID: 17499507 PMCID: PMC1933586 DOI: 10.1016/j.bmcl.2007.04.013] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2007] [Revised: 04/03/2007] [Accepted: 04/04/2007] [Indexed: 11/28/2022]
Abstract
The roles of bacterial RecA in the evolution and transmission of antibiotic resistance genes make it an attractive target for inhibition by small molecules. We report two complementary fluorescence-based ATPase assays that were used to screen for inhibitors of RecA. We elected to employ the ADP-linked variation of the assay, with a Z' factor of 0.83 in 96-well microplates, to assess whether 18 select compounds could inhibit ATP hydrolysis by RecA. The compounds represented five sets of related inhibitor scaffolds, each of which had the potential to cross-inhibit RecA. Although nucleotide analogs, known inhibitors of GHL ATPases, and known protein kinase inhibitors were not active against RecA, we found that three suramin-like agents substantially inhibited RecA's ATPase activity.
Collapse
Affiliation(s)
- Tim J Wigle
- School of Pharmacy, Division of Medicinal Chemistry and Natural Products, The University of North Carolina at Chapel Hill, CB #7360, Chapel Hill, NC 27599-7360, USA
| | | |
Collapse
|
40
|
Wigle TJ, Lee AM, Singleton SF. Conformationally selective binding of nucleotide analogues to Escherichia coli RecA: a ligand-based analysis of the RecA ATP binding site. Biochemistry 2006; 45:4502-13. [PMID: 16584186 DOI: 10.1021/bi052298h] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The roles of the RecA protein in the survival of bacteria and the evolution of resistance to antibiotics make it an attractive target for inhibition by small molecules. The activity of RecA is dependent on the formation of a nucleoprotein filament on single-stranded DNA that hydrolyzes ATP. We probed the nucleotide binding site of the active RecA protein using modified nucleotide triphosphates to discern key structural elements of the nucleotide and of the binding site that result in the activation of RecA for NTP hydrolysis. Our results show that the RecA-catalyzed hydrolysis of a given nucleotide triphosphate or analogue thereof is exquisitely sensitive to certain structural elements of both the base and ribose moieties. Furthermore, our ligand-based approach to probing the RecA ATP binding site indicated that the binding of nucleotides by RecA was found to be conformationally selective. Using a binding screen that can be readily adapted to high-throughput techniques, we were able to segregate nucleotides that interact with RecA into two classes: (1) NTPs that preferentially bind the active nucleoprotein filament conformation and either serve as substrates for or competitively inhibit hydrolysis and (2) nonsubstrate NTPs that preferentially bind the inactive RecA conformation and facilitate dissociation of the RecA-DNA species. These results are discussed in the context of a recent structural model for the active RecA nucleoprotein filament and provide us with important information for the design of potent, conformationally selective modulators of RecA activities.
Collapse
Affiliation(s)
- Tim J Wigle
- School of Pharmacy, Division of Medicinal Chemistry and Natural Products, University of North Carolina, CB #7360, Chapel Hill, North Carolina 27599-7360, USA
| | | | | |
Collapse
|